Rockefeller Capital Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.3M | Sell |
52,192
-917
| -2% | -$588K | 0.05% | 343 |
|
|
2025
Q4 | $35.9M | Sell |
53,109
-644
| -1% | -$439K | 0.06% | 294 |
|
|
2025
Q3 | $34.3M | Sell |
53,753
-1,072
| -2% | -$651K | 0.07% | 266 |
|
|
2025
Q2 | $29.4M | Buy |
54,825
+3,399
| +7% | +$1.63M | 0.06% | 282 |
|
|
2025
Q1 | $21.6M | Sell |
51,426
-1,547
| -3% | -$672K | 0.05% | 340 |
|
|
2024
Q4 | $21.9M | Buy |
52,973
+229
| +0.4% | +$100K | 0.06% | 322 |
|
|
2024
Q3 | $26.6M | Buy |
52,744
+448
| +0.9% | +$218K | 0.07% | 269 |
|
|
2024
Q2 | $25.5M | Buy |
52,296
+436
| +0.8% | +$219K | 0.07% | 253 |
|
|
2024
Q1 | $28M | Sell |
51,860
-620
| -1% | -$339K | 0.08% | 243 |
|
|
2023
Q4 | $29.1M | Sell |
52,480
-147
| -0.3% | -$69K | 0.1% | 216 |
|
|
2023
Q3 | $23M | Buy |
52,627
+1,279
| +2% | +$638K | 0.09% | 236 |
|
|
2023
Q2 | $25.8M | Sell |
51,348
-1,653
| -3% | -$792K | 0.1% | 216 |
|
|
2023
Q1 | $26.5M | Buy |
53,001
+1,341
| +3% | +$642K | 0.11% | 203 |
|
|
2022
Q4 | $21.1M | Buy |
51,660
+81
| +0.2% | +$31.4K | 0.11% | 216 |
|
|
2022
Q3 | $16.8M | Buy |
51,579
+756
| +1% | +$278K | 0.09% | 252 |
|
|
2022
Q2 | $17.8M | Buy |
50,823
+8,500
| +20% | +$3.47M | 0.09% | 224 |
|
|
2022
Q1 | $23.2M | Buy |
42,323
+1,564
| +4% | +$823K | 0.11% | 200 |
|
|
2021
Q4 | $26.8M | Sell |
40,759
-1,194
| -3% | -$750K | 0.13% | 181 |
|
|
2021
Q3 | $26.1M | Sell |
41,953
-12,244
| -23% | -$8.23M | 0.14% | 173 |
|
|
2021
Q2 | $34.2M | Buy |
54,197
+930
| +2% | +$514K | 0.19% | 128 |
|
|
2021
Q1 | $26.1M | Buy |
53,267
+945
| +2% | +$473K | 0.18% | 134 |
|
|
2020
Q4 | $26.2M | Buy |
52,322
+20
| +0% | +$8.95K | 0.2% | 124 |
|
|
2020
Q3 | $20.6M | Sell |
52,302
-698
| -1% | -$258K | 0.19% | 125 |
|
|
2020
Q2 | $17.5M | Buy |
53,000
+108
| +0.2% | +$31.3K | 0.18% | 130 |
|
|
2020
Q1 | $12.8M | Buy |
52,892
+52,256
| +8,216% | +$13.6M | 0.17% | 126 |
|
|
2019
Q4 | $166K | Buy |
636
+172
| +37% | +$45.3K | ﹤0.01% | 819 |
|
|
2019
Q3 | $126K | Hold |
464
| – | – | ﹤0.01% | 725 |
|
|
2019
Q2 | $128K | Sell |
464
-95
| -17% | -$23.4K | ﹤0.01% | 644 |
|
|
2019
Q1 | $125K | Buy |
559
+220
| +65% | +$45.4K | ﹤0.01% | 702 |
|
|
2018
Q4 | $63K | Buy |
339
+292
| +621% | +$59.9K | ﹤0.01% | 498 |
|
|
2018
Q3 | $12K | Hold |
47
| – | – | ﹤0.01% | 555 |
|
|
2018
Q2 | $10K | Buy |
+47
| New | +$9.69K | ﹤0.01% | 601 |
|
Other funds holding IDXX
VCM
VPM
Rockefeller Capital Management's IDXX Position: Q1 2026 in Review
Rockefeller Capital Management reduced its Idexx Laboratories (IDXX) stake by 1.7% in Q1 2026, selling an estimated $588K and leaving 52,192 shares worth $29.3M. The position accounts for 0.05% of the portfolio, ranked #343.
Rockefeller Capital Management first reported a position in IDXX in Q2 2018 and has held it in 32 quarters since. The position peaked at $35.9M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Rockefeller Capital Management held 52,192 shares of Idexx Laboratories worth $29.3M as of Q1 2026.
- Rockefeller Capital Management sold 917 Idexx Laboratories shares in Q1 2026, an estimated $588K.
- Idexx Laboratories made up 0.05% of Rockefeller Capital Management's portfolio in Q1 2026, its #343 holding.
- Rockefeller Capital Management first reported a position in Idexx Laboratories in Q2 2018 and has held it in 32 quarters since.
- Rockefeller Capital Management's Idexx Laboratories position peaked at $35.9M in Q4 2025.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.